country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P99187

Copy Link Print Information

Biologically Validated

Bococizumab

(Synonyms: PF-04950615; RN316)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.80%
CAS. Nr.: 1407495-02-6
Molecular Weight:145.06 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Bococizumab Chemical Structure

CAS. Nr.: 1407495-02-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Verified Bioactivity
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia^[1]^[2].

Isotype

Human IgG2 kappa

Recommend Isotype Controls

Human IgG2 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

PCSK9

In Vivo

Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Pregnant Sprague-Dawley (SD) rats^[1]
Dosage:

0, 10, 30, and 100 mg/kg
Administration:

Intravenous injection (i.v.)
Result:

Decreased in fetal cholesterol levels.
Showed well tolerance and no effects on ovarian or uterine parameters.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

255738 [NCBI]

Accession

Q8NBP7

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG2 kappa

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized PCSK9 Protein, Human can bind Bococizumab. The EC₅₀ for this effect is 2.742 ng/mL.
Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Bococizumab (anti-PCSK9) (HY-P99187). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 kappa (HY-P99002). Black-Unlabelled control, cells without incubation with primary antibody.

Chemical Information

CAS. Nr. 1407495-02-6
Appearance Liquid
Molecular Weight 145.06 kDa
Color Colorless to light yellow
SMILES

[Bococizumab]
Synonyms

PF-04950615; RN316
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (1)

All

Sort by:

Journal Impact Factor

MAbs

Generation of human sequence antibodies in OmniChicken against the highly conserved mammalian target BDNF using three distinct discovery workflows. [Abstract]

2026 Dec;18(1):2672771. PMID: 42237848

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (259 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505. [Content Brief]

[2]. Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Bococizumab

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Biological Activity
Chemical Information
Publications (1)
Reinheit & Dokumentation
Verweise

1/16

Human IgG2 kappa
1/16

Immobilized PCSK9 Protein, Human can bind Bococizumab. The EC₅₀ for this effect is 2.742 ng/mL.
1/16

Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Bococizumab (anti-PCSK9) (HY-P99187). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 kappa (HY-P99002). Black-Unlabelled control, cells without incubation with primary antibody.
1/16

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Bococizumab

Antibody Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Bococizumab

Biologische Aktivität

Chemical Information

Publications (1)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Bococizumab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Antibody Inhibitor Library

Publications Citing Use of MedChemExpress (MCE) Bococizumab

Biologische Aktivität

Chemical Information

Publications (1)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Bococizumab Related Classifications

HY-P99187 Related Classifications